Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

Search through Resources

Home

Clinical Updates Calendar

View All Resources

Search through Resources

TP53 Mutations in EGFR-Mutant and Risk Stratification

Factors Informing First-Line Treatment Selection in EGFR-Mutated NSCLC

Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis

TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC

The Role of Tumor Burden on Treatment Selection in EGFR-Mutated NSCLC

Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar

Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)

Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen

Understanding the Differences Between Chemotherapeutic Agents: The Misconception Driving Today’s Conversations

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

BH-30643 Shows Activity in EGFR C797S+ NSCLC After Resistance to Prior TKI

Emerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLC

Second-Line Sequencing After Frontline Progression in EGFR-Mutated NSCLC

Future Directions and Unmet Needs in in EGFR-Mutant NSCLC

The Evolution of Frontline Therapy in EGFR-Mutant NSCLC

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

Utilizing NCCN Guidelines for Treatment Guidance in EGFR-Mutated NSCLC

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC Infographic

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice

FLAME Data and the Role of ctDNA

The Importance of Combination Therapy: Understanding Chemotherapy’s Role in Modern EGFR+ Treatment

Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC

MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy

Frontline Decision-Making in EGFR-Mutant NSCLC

Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC

Integrating ADCs Into the Treatment Paradigm in in EGFR-Mutant NSCLC

Building a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLC

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic

Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC Infographic

Sacituzumab Tirumotecan Elicits Responses in Previously Treated NSCLC With AGAs Other Than Classical EGFR Mutations

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

Shared Decision-Making With Chemotherapy in EGFR+ NSCLC

Sunvozertinib Improves PFS Over Chemotherapy in First-Line EGFR Exon 20–Mutant NSCLC

Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC

Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC

The Role of Chemotherapy Rechallenge in EGFR-Mutant NSCLC

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

VRN110755 Elicits Responses With Manageable Safety in EGFR C797S+ NSCLC

FLAURA2 Data Show Declining AE Frequency Across Osimertinib Treatment Periods in EGFR+ NSCLC

Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

The Emerging Role of ADCs in EGFR-Mutant NSCLC

Future Directions: Toward Personalized EGFR Therapy in NSCLC

Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance

Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC

Where ADCs Fit in the EGFR+ NSCLC Treatment Paradigm

Impact of Co-Mutations on Treatment Strategies in EGFR-Mutant NSCLC

MET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLC

How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC

Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC

Differentiating Between the Risk-Benefit Profiles for the Combination Therapies

Early FLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC

TP53 Co-Mutation and the TOP Study

Poor Prognostic Factors and Frontline Treatment Selection

Keeping Future Options Open: Flexibility Across the EGFR Treatment Journey

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC

Comparing Intensification Strategies and Toxicity Profiles

Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC

Time Toxicity and Treatment Selection in EGFR-Mutated NSCLC

Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC

Rethinking High-Risk EGFR-Mutant NSCLC

Second-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After Osimertinib